Hana Jansová

433 total citations
19 papers, 365 citations indexed

About

Hana Jansová is a scholar working on Nutrition and Dietetics, Oncology and Molecular Biology. According to data from OpenAlex, Hana Jansová has authored 19 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Nutrition and Dietetics, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Hana Jansová's work include Trace Elements in Health (10 papers), Hemoglobinopathies and Related Disorders (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). Hana Jansová is often cited by papers focused on Trace Elements in Health (10 papers), Hemoglobinopathies and Related Disorders (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). Hana Jansová collaborates with scholars based in Czechia, United States and Australia. Hana Jansová's co-authors include Tomáš Šimůnek, Pavlína Hašková, Miloslav Macháček, Petra Kovařı́ková, Anna Vávrová, Martin Štěrba, Jan Bureš, Jaroslav Roh, Eliška Potůčková and Katherine J. Franz and has published in prestigious journals such as PLoS ONE, Scientific Reports and Free Radical Biology and Medicine.

In The Last Decade

Hana Jansová

19 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hana Jansová Czechia 13 149 105 100 62 59 19 365
Dirk Garmann Germany 13 137 0.9× 130 1.2× 135 1.4× 82 1.3× 23 0.4× 30 552
Anna Vávrová Czechia 11 223 1.5× 208 2.0× 320 3.2× 96 1.5× 83 1.4× 15 689
Mohd. Asif Ansari India 10 100 0.7× 121 1.2× 124 1.2× 62 1.0× 12 0.2× 18 468
Anwar B. Bikhazi Lebanon 12 75 0.5× 112 1.1× 75 0.8× 32 0.5× 26 0.4× 51 350
Pedro M. Politi United States 10 203 1.4× 181 1.7× 186 1.9× 41 0.7× 19 0.3× 18 466
Özlem Kücükoglu Germany 14 42 0.3× 151 1.4× 31 0.3× 58 0.9× 23 0.4× 21 512
Eliška Potůčková Czechia 9 148 1.0× 96 0.9× 14 0.1× 91 1.5× 32 0.5× 15 372
Y Mazurová Czechia 18 181 1.2× 162 1.5× 489 4.9× 48 0.8× 55 0.9× 48 789
Helen M. Eliot United States 8 193 1.3× 212 2.0× 47 0.5× 60 1.0× 21 0.4× 9 409
Julianne M. Davis United States 9 101 0.7× 254 2.4× 29 0.3× 30 0.5× 55 0.9× 10 485

Countries citing papers authored by Hana Jansová

Since Specialization
Citations

This map shows the geographic impact of Hana Jansová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hana Jansová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hana Jansová more than expected).

Fields of papers citing papers by Hana Jansová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hana Jansová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hana Jansová. The network helps show where Hana Jansová may publish in the future.

Co-authorship network of co-authors of Hana Jansová

This figure shows the co-authorship network connecting the top 25 collaborators of Hana Jansová. A scholar is included among the top collaborators of Hana Jansová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hana Jansová. Hana Jansová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Hašková, Pavlína, Lenka Applová, Hana Jansová, et al.. (2022). Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Scientific Reports. 12(1). 9765–9765. 7 indexed citations
2.
Jansová, Hana, Galina Karabanovich, Jaroslav Chládek, et al.. (2021). Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity. Scientific Reports. 11(1). 4456–4456. 5 indexed citations
3.
Jirkovský, Eduard, Markéta Hlaváčková, Hana Jansová, et al.. (2019). In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. Clinical Science. 133(16). 1827–1844. 12 indexed citations
4.
Jansová, Hana, Jaroslav Roh, Danuta S. Kalinowski, et al.. (2019). Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Analytical and Bioanalytical Chemistry. 411(11). 2383–2394. 6 indexed citations
5.
Jansová, Hana & Tomáš Šimůnek. (2019). Cardioprotective Potential of Iron Chelators and Prochelators. Current Medicinal Chemistry. 26(2). 288–301. 17 indexed citations
6.
7.
Bureš, Jan, Hana Jansová, Galina Karabanovich, et al.. (2017). Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology. 392. 1–10. 25 indexed citations
8.
Jansová, Hana, Jan Bureš, Miloslav Macháček, et al.. (2016). Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology. 350-352. 15–24. 14 indexed citations
9.
Hašková, Pavlína, Hana Jansová, Jan Bureš, et al.. (2016). Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. Toxicology. 371. 17–28. 16 indexed citations
10.
Jansová, Hana, Eduard Jirkovský, Jan Bureš, et al.. (2016). Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?. Toxicology. 372. 52–63. 2 indexed citations
11.
Potůčková, Eliška, Jaroslav Roh, Miloslav Macháček, et al.. (2015). In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE. 10(10). e0139929–e0139929. 8 indexed citations
12.
Jirkovský, Eduard, Hana Jansová, Y Mazurová, et al.. (2015). Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Journal of Molecular and Cellular Cardiology. 91. 92–103. 18 indexed citations
13.
Cermanová, Jolana, Eliška Potůčková, Jaroslav Chládek, et al.. (2015). Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget. 6(40). 42411–42428. 40 indexed citations
14.
Bureš, Jan, Hana Jansová, Tomáš Filipský, et al.. (2014). LC–UV/MS methods for the analysis of prochelator—Boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). Journal of Pharmaceutical and Biomedical Analysis. 105. 55–63. 12 indexed citations
15.
Potůčková, Eliška, Hana Jansová, Miloslav Macháček, et al.. (2014). Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs. PLoS ONE. 9(2). e88754–e88754. 26 indexed citations
16.
Potůčková, Eliška, Jan Bureš, Petra Kovařı́ková, et al.. (2014). Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties. PLoS ONE. 9(11). e112059–e112059. 17 indexed citations
17.
Jansová, Hana, Miloslav Macháček, Qin Wang, et al.. (2014). Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radical Biology and Medicine. 74. 210–221. 30 indexed citations
18.
Vávrová, Anna, Hana Jansová, Miloslav Macháček, et al.. (2013). Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells. PLoS ONE. 8(10). e76676–e76676. 59 indexed citations
19.
Vávrová, Anna, Hana Jansová, Pavlína Hašková, et al.. (2012). Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: Novel iron chelators with selective antiproliferative action. Chemico-Biological Interactions. 197(2-3). 69–79. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dirk Garmann Breakdown of academic impact, for papers by Anna Vávrová Breakdown of academic impact, for papers by Mohd. Asif Ansari Breakdown of academic impact, for papers by Anwar B. Bikhazi Breakdown of academic impact, for papers by Pedro M. Politi Breakdown of academic impact, for papers by Özlem Kücükoglu Breakdown of academic impact, for papers by Eliška Potůčková Breakdown of academic impact, for papers by Y Mazurová Breakdown of academic impact, for papers by Helen M. Eliot Breakdown of academic impact, for papers by Julianne M. Davis
Rankless by CCL
2026